The Joint European Compound Library: boosting precompetitive research

Jérémy Besnard; Philip S. Jones; Andrew L. Hopkins; Andrew D. Pannifer

doi:10.1016/j.drudis.2014.08.014

The Joint European Compound Library: boosting precompetitive research

Jérémy Besnard
, Philip S. Jones
, Andrew L. Hopkins
, Andrew D. Pannifer (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

66 Citations (Scopus)

351 Downloads (Pure)

Abstract

The Joint European Compound Library (JECL) is a new high-throughput screening collection aimed at driving precompetitive drug discovery and target validation. The JECL has been established with a core of over 321000 compounds from the proprietary collections of seven pharmaceutical companies and will expand to around 500000 compounds. Here, we analyse the physicochemical profile and chemical diversity of the core collection, showing that the collection is diverse and has a broad spectrum of predicted biological activity. We also describe a model for sharing compound information from multiple proprietary collections, enabling diversity and quality analysis without disclosing structures. The JECL is available for screening at no cost to European academic laboratories and SMEs through the IMI European Lead Factory (http://www.europeanleadfactory.eu/).

Original language	English
Pages (from-to)	181-186
Number of pages	6
Journal	Drug Discovery Today
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.drudis.2014.08.014
Publication status	Published - Feb 2015

Access to Document

10.1016/j.drudis.2014.08.014

1-s2.0-S1359644614003419-mainFinal published version, 1.24 MB

Cite this

@article{3b39d0353fc74c1a87304bda0a8ab04b,

title = "The Joint European Compound Library: boosting precompetitive research",

abstract = "The Joint European Compound Library (JECL) is a new high-throughput screening collection aimed at driving precompetitive drug discovery and target validation. The JECL has been established with a core of over 321000 compounds from the proprietary collections of seven pharmaceutical companies and will expand to around 500000 compounds. Here, we analyse the physicochemical profile and chemical diversity of the core collection, showing that the collection is diverse and has a broad spectrum of predicted biological activity. We also describe a model for sharing compound information from multiple proprietary collections, enabling diversity and quality analysis without disclosing structures. The JECL is available for screening at no cost to European academic laboratories and SMEs through the IMI European Lead Factory (http://www.europeanleadfactory.eu/).",

author = "J{\'e}r{\'e}my Besnard and Jones, \{Philip S.\} and Hopkins, \{Andrew L.\} and Pannifer, \{Andrew D.\}",

year = "2015",

month = feb,

doi = "10.1016/j.drudis.2014.08.014",

language = "English",

volume = "20",

pages = "181--186",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - The Joint European Compound Library

T2 - boosting precompetitive research

AU - Besnard, Jérémy

AU - Jones, Philip S.

AU - Hopkins, Andrew L.

AU - Pannifer, Andrew D.

PY - 2015/2

Y1 - 2015/2

N2 - The Joint European Compound Library (JECL) is a new high-throughput screening collection aimed at driving precompetitive drug discovery and target validation. The JECL has been established with a core of over 321000 compounds from the proprietary collections of seven pharmaceutical companies and will expand to around 500000 compounds. Here, we analyse the physicochemical profile and chemical diversity of the core collection, showing that the collection is diverse and has a broad spectrum of predicted biological activity. We also describe a model for sharing compound information from multiple proprietary collections, enabling diversity and quality analysis without disclosing structures. The JECL is available for screening at no cost to European academic laboratories and SMEs through the IMI European Lead Factory (http://www.europeanleadfactory.eu/).

AB - The Joint European Compound Library (JECL) is a new high-throughput screening collection aimed at driving precompetitive drug discovery and target validation. The JECL has been established with a core of over 321000 compounds from the proprietary collections of seven pharmaceutical companies and will expand to around 500000 compounds. Here, we analyse the physicochemical profile and chemical diversity of the core collection, showing that the collection is diverse and has a broad spectrum of predicted biological activity. We also describe a model for sharing compound information from multiple proprietary collections, enabling diversity and quality analysis without disclosing structures. The JECL is available for screening at no cost to European academic laboratories and SMEs through the IMI European Lead Factory (http://www.europeanleadfactory.eu/).

UR - https://www.scopus.com/pages/publications/84922917237

U2 - 10.1016/j.drudis.2014.08.014

DO - 10.1016/j.drudis.2014.08.014

M3 - Article

C2 - 25205347

SN - 1359-6446

VL - 20

SP - 181

EP - 186

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 2

ER -

The Joint European Compound Library: boosting precompetitive research

Abstract

Access to Document

Other files and links

Fingerprint

Cite this